Menu

Sudden Infant Death Tied to Serotonin

One-third of babies who died of SIDS had higher-than-normal levels of the neurotransmitter in their blood serum, according to a study. 

Jul 3, 2017
Kerry Grens

PIXABAY, SHAUN_PALMERA subset of children who died from sudden infant death syndrome (SIDS) had elevated levels of the neurotransmitter serotonin in their blood serum, researchers report today (July 3) in PNAS. The authors say the results add to the evidence that serotonin may be involved in some SIDS cases.

A previous study by the same researchers observed serotonin abnormalities in about 40 percent of SIDS cases, namely, low levels of serotonin in the brainstem. To see what’s happening outside the brain with serotonin, the team measured serotonin levels in the serum of 61 babies who had died of SIDS and compared that to the levels of 15 autopsied controls. They found that one-third of the SIDS cases had serotonin levels two standard deviations higher than the control babies’ levels.

“These findings suggest the potential of a high serum serotonin level as a forensic biomarker at autopsy to differentiate SIDS deaths with serotonergic defects from other causes of sudden death and, importantly, as evidence of a peripheral [serotonin] abnormality in SIDS,” the researchers wrote in PNAS.

See “Kids’ Sudden Cardiac Deaths Explained by Heritable Mutations in a Single Gene

The rate of SIDS has dropped considerably since the late 1980s. Public health officials have attributed that decline to safe sleeping practices, such as placing babies in an uncluttered crib on their backs, and other preventive measures. But SIDS is the leading cause of infant deaths, responsible for four deaths among every 10,000 live births, according to the report, and many questions remain about its cause.

“Just as important with these findings is that we are getting closer to identifying causal mechanisms for SIDS. The welcome fall in [SIDS-death] rates is due to good risk-reduction advice rather than an increased understanding of why these infants die,” Peter Blair, an epidemiologist at the University of Bristol who was not involved in the study, tells The Atlantic.

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.